Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density.
Bone density (BD) was evaluated by single photon absorptiometry (SPA) in 18 women treated with Buserelin a gonadotrophin-releasing hormone (LHRH) analogue, for uterine fibroids. Buserelin was administered for a period of 6 mth. Amenorrhoea and oestradiol levels in the follicular-phase range were recorded in all patients during treatment. Fibroid volume was evaluated by means of ultrasound. SPA was performed at the 1/3 proximal radius and at the 1/10 distal radius sites before starting therapy and every 2 mth subsequently for 12 mth. BD was also measured in a control group of 18 normally-menstruating premenopausal women, matched for age and body mass index. No significant changes in BD at the proximal or distal radius sites were observed in either the cases or the controls during the study. Moreover, comparison of the data on the cases and the controls revealed no differences in BD at 0, 6 or 12 mth. Thus, although LHRH analogue treatment proved effective in reducing fibroids, it did not cause any significant changes in BD.
Bianchi
G
G
Institute E. Bruzzone, Rheumatological Centre, University of Genoa, Italy.
Costantini
S
S
Anserini
P
P
Rovetta
G
G
Monteforte
P
P
Menada
M V
MV
Fagà
L
L
De Cecco
L
L
D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D002064:Buserelin / Q000494:pharmacology* / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004958:Estradiol; D002064:Buserelin